Japan in the Global Picture* October 6, 2015

EFPIA Japan Days

Stefan Oschmann
Vice President, European Federation of Pharmaceutical Industries & Associations (EFPIA)
President, International Federation of Pharmaceutical Manufactures & Associations (IFPMA)
Vice Chairman of the Executive Board & Deputy CEO of Merck

www.efpia.eu

Europe & Japan Facing an Aging Society
Declining fertility rates & longer lifespanscreating new healthcare challenges

European Union (2014)

Japan (2014)

Source: The CIA Fact Book. (2014). European Reunion – Population Pyramid. Retrieved fromhttps://www.cia.gov/library/publications/the-world-factbook/geos/eu.html

Source: The CIA Fact Book. (2014). Japan – Population Pyramid. Retrieved form
https://www.cia.gov/library/publications/the-world-factbook/geos/ja.html

www.efpia.eu

2Non-Communicable Diseases (NCDs):a challenge for all health systems

900000

Number of Cancer Cases

800000Cancer Incidence on the Rise in Japan

7000006000005000004000003000002000001000000Year
Source: Cancer Information Service, National Cancer Center. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H
and The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25
Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Japanese Journal of ClinicalOncology, 44(4): 388-396, 2013 Retrieved from http://ganjoho.jp/en/professional/statistics/table_download.html

www.efpia.eu

3

Universal Care: Lessons From Japan
Health Spending in OECD Countries as Percent of GDP

10.3% of GDP

Source: Organization for Economic Cooperation and Development (OECD). (2014). OECD Health Statistics 2014—How does
Japan compare? Retrieved from: http://www.oecd.org/els/health-systems/Briefing-Note-JAPAN-2014.pdf

www.efpia.eu

4Taking a Proactive Approach toHealthcare System Challenges
Improved PMDA Review Times

PMDA has nearly eliminated Japan’s ‘drug lag’
45
40

Average Review Time

3530

10.1 Months!!

Number of NME

28.3

25
20

16.8

17.7

19.1

21.5

22.8
20

18.3

19

19.1
14.8

15
10

10.1

9.5

10.1

2011

2012

2013

50
2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

Source: 医薬産業政策研究所. 2014. 日本における新薬の臨床開発と認審査の実積 (No. 63, p. 21).

2010www.efpia.eu

5The Environment for Innovation is Diverse
Origins of 252 new drugs discovered between
1998 and 2007

Biotechnology company; or universitydiscovered, transferred to biotechnology
company in the same region
Large pharmaceutical company

University-discovered, transferred tobiotechnology company in different
regionUniversity-discovered, transferred topharmaceutical company

Small pharmaceutical company

Source: Kneller, Robert. (November 2010). The importance of new companies for drug discovery: origins of a decade of newdrugs. Nature Reviews Drug Discovery. Retrieved from http://www.nature.com/nrd/journal/v9/n11/full/nrd3251.html

www.efpia.eu

6Creating an Environment forInnovation & Health Improvement
Public-Private Partnerships (PPPs)
E.g., Academia-IndustryGovernment
Free Trade Agreements &Increased FDI
EU-Japan
FTA

Reward for Innovation
E.g., Permanence of Pricing
Premium for Innovation

Innovative Regulatory Policy
E.g., Regulatory Harmonization,
Adaptive Licensing, Sakigake (FastTrack) Designation, etc.

Freeing Capital &Transparency for GrowthE.g., Corporate Governance
Reform, Corporate Tax Rate
Reformwww.efpia.eu

7Role of Public Private Partnerships (PPPs)
PPPs can both spur innovation and solve global health challenges

European Union

Japan

www.efpia.eu

8The Necessary Components toImprove HealthInnovation
FriendlyPoliciesDisruptive
Innovation

SolutionsforHealthcarewww.efpia.eu

9Thank You!
EFPIA Brussels Office
Leopold Plaza Building * Rue du Trône 108
B-1050 Brussels * Belgium
Tel: + 32 (0)2 626 25 55
www.efpia.eu * info@efpia.eu